Document:

Letter Amendment to License, Research & Development Agreement

 Exhibit 10.33 
  
 December 10, 2003 
  
 Mr. Lonnie Moulder 
 President and CEO 
 MGI PHARMA, INC. 
 5775 West Old Shakopee Road 
 Suite 100 
 Bloomington, MN 55437-3174 
  

	Re:	The License, Research and Development Agreement dated August 2, 2000 between MethylGene, Inc. (MG) and MGI PHARMA, INC. (MGI) (the “Agreement”)

  
 Dear Lonnie: 
  
 The purpose of this letter is to amend and capture the current understanding between our
companies regarding the status of the above referenced Agreement. With this letter, MethylGene agrees that: 
  

	 	(1)	Upon MGI’s payment to MethylGene no later than December 15, 2003 of US $1,549,300 (aggregate of amount MG paid for 1 kg of MG98 API and R&D Contract Costs through June 30,
2004), MGI will have satisfied all life-to-date R&D Contract Costs under the Agreement and have satisfied all minimum R&D Contract Costs required by the Agreement. 

  

	 	(2)	No additional MG98 R&D Contract Costs or financial obligations under Third Party Agreements will be incurred by MGI or become due to MethylGene under the Agreement during the
time period commencing on January 1, 2004 and continuing until 60 days following MethylGene’s closing of the database for the Phase I/II trial of MG98 in combination with interferon alpha in metastatic renal cell cancer (the “MGI MG98
Resumption Decision Date”). 

  

 1 

 December 10, 2003 
 Mr.
Lonnie Moulder 
  

	 	(3)	MGI will contribute MG98 API and any residual MG98 drug supply from the AML/MDS trial when the trial report is issued as well as continue to collaborate in the areas of GMP
manufacturing support and consultation, protocol development and approval, clinical trial consultation and overview for the MG98 Phase I/II trial of MG98 in combination with interferon alpha in metastatic renal cell cancer until after the MGI MG98
Resumption Decision Date. It is agreed MG will retain responsibility for the clinical operations of the trial. 

  

	 	(4)	The prohibition that MGI may not research, develop or commercialize itself or with any third party, any compound or product that inhibits the DNA methyltransferase enzyme as stated
in Article 3.2(a) of the Agreement is waived for 5-AZA-C compounds and analogs under development. 

  

	 	(5)	MethylGene waives its right to terminate the Agreement under Article 12.2, under the respective Products until after the MGI MG98 Resumption Decision Date and MGI DNA MT Resumption
Decision Date respectively. 

  

	 	(6)	The MG98 IND will be received by MethylGene from MGI in order for MG to run and be operationally responsible for the MG98 Phase I/II trial in combination with interferon alpha in
metastatic renal cell cancer. 

  

	 	(7)	MGI will have no additional DNA MT R&D Contract Costs or financial obligations under Third Party Agreements due to MethylGene under the Agreement during the time period
commencing January 1, 2004 and continuing until July 30, 2004 (the “MGI DNA MT Resumption Decision Date”). MGI shall decide on July 30, 2004 if it will continue funding the DNA MT R&D project and if MGI declines then all rights will
revert back to MethylGene in North America. 

  

	 	(8)	MGI has no further research obligations for DNA MT until after the MGI DNA MT Resumption Decision Date and MG will provide a research report and/or meeting with MGI by June 30,
2004. If MGI elects to continue funding the DNA MT R&D project after the MGI DNA MT Resumption Decision Date then its research obligations will be discussed and mutually agreed with MethylGene. 

  

	 	(9)	MGI will close out and complete the final report for the AML/MDS trial conducted in the U.S. under GCP conditions and supply such information to MG for its use.

  

 2 

 December 10, 2003 
 Mr.
Lonnie Moulder 
  

	 	(10)	Any expenditures or costs made or absorbed by MG during the course of research for DNA MT or development of MG98 including any financial obligations under Third Party Agreements
will be credited toward its contribution contemplated under Article 4.2 of the Agreement if MG gives notice to exercise its co-promotion options for each Product, respectively. 

  
 Except as expressly modified by the terms of this letter, the terms and conditions of the
Agreement and its respective Exhibits will remain in full force and effect. 
  
 Sincerely, 
  
 /s/Donald F. Corcoran 
  
 Donald F. Corcoran 
 President & CEO 
  

			
	 Agreed to and accepted, this 15th
 day
of December, 2003
  
  
 MGI PHARMA, INC.

		
	By:	 	/s/    Leon O Moulder, Jr.        
	 	 	

	 	 	 Leon O. Moulder. Jr.
 President and CEO

  

	cc:	Bill Brown, Executive Vice President & Chief Financial Officer, MGI PHARMA, INC. 

	Klaus	Kepper, Vice President Finance and Chief Financial Officer, MethylGene Inc. 

  

 3Terms and Conditions Regarding the Grant of Awards to Non-Employee Directors

 Exhibit 10.17(c) 
  

Terms and Conditions Regarding the Grant of Awards 
 to Non-Employee Directors under the 
 2003 Equity Incentive Plan 
 of 
 Manpower Inc. 
  
 (Amended and Restated Effective January 1, 2004) 
  

	 	1.	Definitions 

  
 Unless the context otherwise requires, the following terms shall have the meanings set forth below: 
  
 (a) “Average Trading Price” shall mean the average of the Market
Prices on the last trading day of each full or partial calendar quarter covered by an Election Period; provided, however, that with respect to the Election Period beginning on July 29, 2003, “Average Trading Price” shall mean
the average of the Market Price on November 7, 2003 and the Market Price on the last trading day of the last full or partial calendar quarter covered by that Election Period. 
  
 (b) A “Commencement Date” shall mean, with respect to Directors in office as of July 29, 2003, July 29, 2003 and
thereafter January 1st of any year, shall mean, with respect to Directors appointed to the Board of Directors after
July 29, 2003, the date of the Director’s initial appointment to the Board of Directors and thereafter January 1st of any year, and shall mean, with respect to individuals who were Employee members of the Board of Directors and who become Directors after July 29, 2003, the date on which such individual becomes a Director and thereafter January
1st of any year. 
  
 (c) An “Election Period” shall mean a period of time beginning on a Commencement Date and ending on the earlier of (a) the date of termination
of a Director’s tenure as a Director or (b) the next succeeding December 31st. 
  
 (d) “Equity Plan” shall mean the 2003 Equity Incentive Plan of
Manpower Inc. 
  
 (e) “Option” shall mean a Nonstatutory
Stock Option granted under the Equity Plan. 
  
 (f)
“Retainer” shall mean the annual cash retainer payable to a Director as established from time to time by the Board of Directors; provided, however, that the term “Retainer” shall not include that portion of the
annual cash retainer as to which a right exists to make an election under, or for which a prior election is in effect under, the Terms and Conditions Regarding the Grant of Options in Lieu of Cash Directors Fees to Non-Employee Directors Under 2003
Equity Incentive Plan of Manpower Inc. (the “Option Terms”) or the Procedures Governing the Grant of Options to Non-Employee Directors Under the 1994 Executive Stock Option and Restricted Stock Plan of Manpower Inc. (the “Option
Procedures”). 

 (g) “Retirement” shall mean a Director’s termination of membership on the Board of
Directors at a time when (1) the Director is age 60 or older and has served at least five years on the Board of Directors, or (2) the Director has served at least ten years on the Board of Directors. 
  
 Any capitalized terms used below which are not otherwise defined above will
have the meanings assigned to them in the Equity Plan. 
  

	 	2.	Right to Elect Deferred Stock. 

  
 Within ten days after the Commencement Date of each Election Period, a Director may elect to receive, in lieu of the Retainer to which he or she would
otherwise be entitled for that Election Period, Deferred Stock granted in accordance with the following. The election shall cover 50 percent, 75 percent or 100 percent of the Retainer payable to the Director for the Election Period. The election to
receive Deferred Stock in lieu of the Retainer must be made within ten days after the commencement of the Election Period covered by the election, except that for an election made by a Director (a) for the Election Period beginning on July 29, 2003,
the election may be made by November 7, 2003 or (b) in connection with his or her initial appointment to the Board of Directors or otherwise becoming a Director, the election may be made within the first 10 days following the date of such
appointment or attaining such status. Notwithstanding the foregoing, no Director who is a resident of the United Kingdom shall be eligible to make an election hereunder but rather shall be required to receive Deferred Stock in lieu of 100 percent of
the Retainer and, as such, treated as if he or she had made an election covering a period beginning on each Commencement Date and ending on the expiration of the Election Period beginning on such date. The number of shares of Deferred Stock granted
with respect to each Election Period shall equal (a) the amount of the Retainer payable to the Director for that Election Period to which the election relates, divided by (b) the Average Trading Price (rounded to the fourth decimal place). Said
election shall be in writing and delivered to the Secretary of the Company. The date of grant of the Deferred Stock shall be the last trading day of the Election Period covered by the election. The Company shall effect the granting of Deferred Stock
under these Terms and Conditions by the execution of Deferred Stock Agreements. 
  

	 	3.	Deferred Stock: General Provisions 

  
 (a) Distribution of Shares. The Company shall settle Deferred Stock in Shares. Deferred Stock granted to Directors shall be fully vested on the
date of grant. Shares shall be distributed in respect of Deferred Stock within 30 days after the date of termination of a Director’s tenure as a Director; provided, however, that if the distribution of such Shares would occur
outside of a “Trading Window” (as defined in the Manpower Inc. Statement of Policy on Securities Trading), then the Company may delay the distribution of such Shares until the beginning of the next “Trading Window”. 

 
 (b) Dividends and Distributions. As of the end of each Election
Period, each Director shall be granted a number of additional shares of Deferred Stock equal to the amount of dividends which would have been received by a shareholder of record of a number of Shares equal to the number of shares of Deferred Stock
held by such Director immediately before such 
  

 2 

 dividend, divided by the Average Trading Price. In the event of any distribution with respect to Shares other than a cash
dividend, then at the end of each Election Period each Director shall be granted a number of additional shares of Deferred Stock equal to the number of Shares which could have been purchased at the Average Trading Price with an amount equal to the
fair market value of the consideration which would have been received by a shareholder of record of a number of Shares equal to the number of shares of Deferred Stock held by such Director immediately before such dividend. 
  

	 	4.	Transition Provisions 

  
 Except as provided below, the Option Terms and the Option Procedures are terminated effective July 29, 2003. All elections in effect as of July 29, 2003
under the Option Terms and the Option Procedures shall remain in effect. Directors in office prior to July 29, 2003 for whom an election is not in effect under the Option Terms or the Option Procedures covering the full period from November 5, 2001
through November 4, 2006 will continue to have the right to make elections under the Option Terms with respect to the first $50,000 of the annual cash retainer through November 4, 2006. 
  

	 	5.	Annual Option Grant 

  
 On the date of the meeting of the Board of Directors closest to October 31st of each year, each Director shall be granted an Option to purchase 5,000 Shares. If the date of a Director’s initial appointment to the Board of
Directors is: 
  

	 	(a)	after the date of that meeting of the Board of Directors, but on or before December 31st of that year, the Director shall be granted an Option to purchase 5,000 Shares; 

  

	 	(b)	on or after January 1st of the following year,
but on or before March 31st of such year, then the Director shall be granted an Option to purchase 3,750 Shares;

  

	 	(c)	on or after April 1st of the following year, but
on or before June 30th of such year, then the Director shall be granted an Option to purchase 2,500 Shares;

  

	 	(d)	on or after July 1st of the following year, but
on or before September 30th of such year, then the Director shall be granted an Option to purchase 1,250 Shares; and

  

	 	(e)	on or after October 1st of the following year,
but before the date of the meeting of the Board of Directors closest to October 31st of such year, then the Director
shall not be granted an Option to purchase any Shares until the grant to be made at such meeting. 

  
 Options to be granted in accordance with clauses (a) through (d), above, shall be granted on the date of the meeting of the Board of Directors next
following the date of the Director’s appointment to the Board of Directors. Each Option granted hereunder shall have an exercise price equal to the Market Price on the business day immediately preceding the date of grant, and shall be
immediately exercisable on the date of grant, and shall remain exercisable until the earlier of ten years after the date of grant, or three years after the date the Director’s membership 
  

 3 

 on the Board of Directors terminates because of death or upon the Disability or Retirement of the Director, or 18 months
after the date the Director’s membership on the Board of Directors terminates in any other circumstances. The Board of Directors may in its sole discretion increase the periods permitted for exercise of an Option if a Director ceases to be a
Director as provided above, if allowable under applicable law; provided, however, in no event shall an Option be exercisable subsequent to ten years after its date of grant. 
  

	 	6.	Application of Plan. 

  
 Except as otherwise provided in these Terms and Conditions, the Equity Plan shall apply to any Deferred Stock and Options granted pursuant to these Terms
and Conditions. 
  

 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]